Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Sh... ( SEATTLE June 17 2011 /- Cell Therapeu...)

Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders

Date:6/17/2011

SEATTLE, June 17, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today the results from its Special Meeting of Shareholders held on Friday, June 17, 2011. At the meeting, shareholders approved the proposal to amend CTI's amended and restated articles of incorporation to increase the total number of authorized shares and authorized shares of common stock.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties include the risk factors listed or described from time to time in CTI's filings with the U.S. Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: deramian@ctiseattle.com
www.CellTherapeutics.com/press_room

Investors Contact:
Ed Bell
T: 206.282.7100
Lindsey Jesch Logan
T: 206.272.4347
F: 206.272.4434
E: invest@ctiseattle.com

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine technology :

1. Serina Therapeutics, Inc. Closes $9.5 Million Financing Round
2. Cancer Research UK Signs Deal With Centella Therapeutics, Inc. to Launch Clinical Development of Radiotherapy-Enhancing Drug
3. Cell Therapeutics, Inc. Announces Institutional Investors Purchase Approximately $16.0 Million of Preferred Stock and Warrants
4. Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results
5. Vista Partners Updates Coverage on Opexa Therapeutics, Inc.; Maintains Target Price of $6.50
6. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
7. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End 2010 Financial Results on February 16
8. Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
9. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for Pixuvri®
10. Veteran Pharmaceutical Executives Form New American Therapeutics, Inc.
11. BioMolecular Therapeutics, a New Global Player in RNAi Therapeutics, Launches Company and Adds Key Advisors

Post Your Comments:

(Date:5/20/2013)... , May 20, 2013 Hyland ... healthcare industry by creating the Multi-Disciplinary Clinical Leadership ... variety of medical experts with diverse healthcare experience, ... healthcare industry to create new software solutions that ... specific needs of patients and staff. ...

(Date:5/20/2013)... 20, 2013 Enrollment of patients with Type ... dose-finding clinical trial of product candidate NewMet ™, ... for Type 2 diabetes. Elcelyx expects to complete enrollment ... June. Results of the trial,s primary endpoint of change ... and the read-out for long-term glucose lowering and weight ...

(Date:5/20/2013)... Rhythm announced today the presentation of results from ... gastroparesis symptoms among diabetic patients in the U.S. than ... patients with both type 1 and type 2 diabetes, ... the more common type 2 disease. ... Professor of Medicine at Harvard Medical School and Director ...

Breaking Medicine Technology:Hyland Software Forms Multi-Disciplinary Clinical Leadership Team to Augment Healthcare Solutions 2 Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2 Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3 Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4 Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 2 Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 3 Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 4

[0] Hyland Software Forms Multi-Disciplinary Clinical Leadership Team to Augment Healthcare Solutions [0] Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes [0] Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S.

... 2008 Senesco,Technologies, Inc. ("Senesco" or the "Company") ... Mirmira, one of the Company,s funded researchers, will,be ... data,at two conferences in April 2008. Dr. Mirmira, ... of Virginia, is presently the,Eli Lilly Endowed Chair ...

... of Athletes ... - Team Type 1, - Spreads Messages of Hope to Others ... Ultimate Goal of Tour de France Competition, BRIDGEWATER, ... injection) will now become the primary sponsor of,Team Type 1, a team of amateur ...

Cached Medicine Technology:Senesco's Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences 2 Senesco's Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences 3 Elite Team of Cyclists with Type 1 Diabetes Powers Forward in 2008 Sponsored by Rapid-Acting Insulin Apidra(R) 2 Elite Team of Cyclists with Type 1 Diabetes Powers Forward in 2008 Sponsored by Rapid-Acting Insulin Apidra(R) 3 Elite Team of Cyclists with Type 1 Diabetes Powers Forward in 2008 Sponsored by Rapid-Acting Insulin Apidra(R) 4 Elite Team of Cyclists with Type 1 Diabetes Powers Forward in 2008 Sponsored by Rapid-Acting Insulin Apidra(R) 5

Senesco's Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences Elite Team of Cyclists with Type 1 Diabetes Powers Forward in 2008 Sponsored by Rapid-Acting Insulin Apidra(R)

(Date:5/20/2013)... University of Southampton has shown that blind and visually ... to that used by bats and dolphins, to determine ... is published in the journal Hearing Research , ... could help blind people with spatial awareness and navigation. ... impairment and how to optimise echolocation ability in order ...

(Date:5/20/2013)... 6Webs.com is the leading supplier of ... 6Webs.com recently completed their assessments of the top alarm ... annually and the top home security system companies are ... technology, equipment and warranties to mention a few. ... team completed the home security reviews, numerous people claimed ...

(Date:5/20/2013)... Dermatologists are saying that new federally mandated labeling ... choices when it comes to products that provide ... required by the U.S. Food and Drug Administration ... will protect against skin cancer in addition to ... a sunscreen is water-resistant, according to the American ...

(Date:5/20/2013)... VHA Inc., the national health care ... population health improvement, announced a new offering to ... pursue population health management with a strategic ... the transition to value-based models of care. As ... of services, the offering integrates VHA expert advisory ...

(Date:5/20/2013)... Researchers at Lund University in Sweden have mapped ... atherosclerotic disease. No studies have previously examined whether ... study looked at coronary heart disease, ischemic stroke, ... in individuals whose siblings and parents have suffered ... showed that heredity is highest for atherosclerosis of ...

Breaking Medicine News(10 mins):Health News:New study finds blind people have the potential to use their 'inner bat' to locate objects 2 Health News:Best Home Alarm System Companies in 2013 Published by Leading Security Reviews Site - 6Webs.com 2 Health News:Revised Sunscreen Labels Should Help Consumers Make Wiser Choices 2 Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 2 Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 3 Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 4

[0] New study finds blind people have the potential to use their 'inner bat' to locate objects [0] Best Home Alarm System Companies in 2013 Published by Leading Security Reviews Site - 6Webs.com [0] Revised Sunscreen Labels Should Help Consumers Make Wiser Choices [0] VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings [0] Atherosclerotic disease heredity mapped in nationwide study

... MKL ) reported diluted net loss per share ... to diluted net income per share of $9.26,for the ... was $2.63 for the,nine months ended September 30, 2008 ... the same period of 2007. The results for both ...

... more targeted prevention efforts, researcher says , , TUESDAY, Nov. 4 ... Hispanics in the United States, a new study shows. , ... a type of beverage that is more associated with risky ... developed to target that beverage and that type of drinking," ...

... HAVEN, Conn., Nov. 4 VION,PHARMACEUTICALS, INC. (OTC Bulletin ... on Thursday, November 6, 2008 to,discuss its 2008 third ... 8:30 a.m. Eastern Time., To participate in the ... 213-8858 for international callers), at least 15 minutes,before the ...

... 4, 2008 Proactive measures can reduce hip fracture rates ... as 50 percent -- among those at risk, according to ... was published online on November 3 by The Journal ... , The largest study of its kind, the five-year study ...

... be Held at 8 a.m. EST -, SHENZHEN, ... (NYSE: NPD ) ("China Nepstar" or the "Company"), ... of directly operated,stores, announced today that the Company will ... before the market opens on,Wednesday, November 26, 2008., ...

... (Nasdaq: IRIX ) today reported financial results for ... the third quarter of 2008 was $12.0 million, an ... quarter of 2007. The,Company recorded net loss of $0.2 ... of 2008, an improvement over the net loss of ...

Markel Reports Third Quarter and Nine-Month Results Study Shows Hispanics Prefer Beer Vion Updates Conference Call Information Healthy bones program reduces hip fractures by 37 percent China Nepstar Chain Drugstore to Announce Third Quarter 2008 Financial Results on November 26 IRIDEX Reports Third Quarter 2008 Financial Results

... IMMULITE 1000 assays are designed ... and IMMULITE 1000, continuous random ... simplicity in both design and ... found in a wide variety ...

... Digoxin Assay is a homogeneous ... in the quantitative analysis of ... plasma. Kits are packaged specifically ... COBAS MIRA, COBAS MIRA S, ...

The Emit 2000 Digoxin Assay is a homogeneous enzyme immunoassay for use in the quantitative analysis of digoxin in human serum or plasma. Kits are conveniently packaged in Olympus Reagent Cartridges ...

Liquichek Rheumatoid Factor Control is a liquid trilevel control designed to monitor rheumatoid factor testing procedures, including nephelometric and latex agglutination methods....

Medicine Products:

IMMULITE Phenytoin Emit 2000 (Convenience Pack) Digoxin Assay OSR Digoxin Assay Liquichek Rheumatoid Factor Control